Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells

6Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Intracellular vimentin overexpression has been associated with epithelial- mesenchymal transition, metastasis, invasion, and proliferation, but cell surface vimentin (CSV) is less understood. Furthermore, it remains unknown whether CSV can serve as a therapeutic target in CSV-expressing tumor cells. We found that CSV was present on glioblastoma multiforme (GBM) cancer stem cells and that CSV expression was associated with spheroid formation in those cells. A newly developed monoclonal antibody against CSV, 86C, specifically and significantly induced apoptosis and inhibited spheroid formation in GBM cells in vitro. The addition of 86C to GBM cells in vitro also led to rapid internalization of vimentin and decreased GBM cell viability. These findings were associated with an increase in caspase-3 activity, indicating activation of apoptosis. Finally, treatment with 86C inhibited GBM progression in vivo. In conclusion, CSV-expressing GBM cells have properties of tumor initiating cells, and targeting CSV with the monoclonal antibody 86C is a promising approach in the treatment of GBM.

Cite

CITATION STYLE

APA

Noh, H., Yan, J., Hong, S., Kong, L. Y., Gabrusiewicz, K., Xia, X., … Li, S. (2016). Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget, 7(44), 72021–72032. https://doi.org/10.18632/oncotarget.12458

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free